ESGO 2026 - Round 3 - ESGO Congress

Put Your Knowledge of Surgical Approaches in Gynaecological Oncology

To The Test

See How You Measure Up!

Let’s start.

1.

At the time of ESGO 2026, are there any ADCs approved in endometrial cancer by the EMA?

ESGO 2026 Scientific session: The Era of ADCs in Gynaecological Malignancies

No, because ADCs are ineffective in gynaecological cancers

Yes, mirvetuximab soravtansine is approved for endometrial cancer

No, there are no ADCs approved for endometrial cancer

Yes, several ADCs are approved for endometrial cancer

1 out of 3

2.

Is pneumonitis or interstitial lung disease (ILD) a class effect of ADCs?

ESGO 2026 Scientific session: The Era of ADCs in Gynaecological Malignancies

No, ILD is only seen with one specific ADC

Yes, ILD occurs uniformly and frequently (>5%) with all ADCs

No, ILD is unrelated to ADC mechanisms

Yes, pneumonitis or ILD can be considered a class effect of ADCs, although incidence rates vary widely

2 out of 3

3.

What is the state of the art for immunotherapy and its impact in gynaecological cancer?

ESGO 2026 Scientific session: Current and Future Landscape of Immunotherapy

Immunotherapy has completely replaced chemotherapy

Immunotherapy has yielded remarkable results in selected subtypes, although response rates remain modest in others

Immunotherapy has no established role in gynaecological oncology

Immunotherapy is highly effective across all gynaecologic cancer subtypes

3 out of 3

Kindly fill in your details and submit your answers to reveal the results.

Name

Email

Country